Rohto Pharmaceutical stock sets FY2031 growth targets

Published on 10/07/2026 at 00:55 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Rohto Pharmaceutical stock trades at JPY 2,718 on October 6 after the October 5 strategy update. Q1 EPS reached JPY 47.14 versus JPY 39.86 expected.

Rohto, JP3982400008, Illustration mit AI erstellt.

Rohto Pharmaceutical (ISIN JP3982400008) was last at JPY 2,718 on the Tokyo Stock Exchange on October 6, 2026, with a market capitalization of JPY 614.2 billion. The company set new FY2031 financial targets in an October 5 strategy update, placing long-term growth ahead of the immediate share-price signal.

FY2031 targets reset the scale

According to Japan IR on October 5, 2026, Rohto now targets FY2031 net sales of JPY 464.0 billion and operating income of JPY 59.8 billion. The forecast also carries a 12.9 percent operating margin, a 56 percent overseas sales ratio and a 40 percent dividend payout ratio.

The target mix matters because it combines international expansion with shareholder returns. Rohto describes the rolling plan as a move across self-care, professional care, technology-led products and healthcare, while maintaining a DOE target of 4.0 percent, according to Japan IR.

Q1 earnings beat the estimate

Rohto's latest reported quarter added a nearer-term operating checkpoint. The company delivered EPS of JPY 47.14 against a JPY 39.86 estimate, an 18.3 percent positive surprise, in the results published for the quarter on August 5, 2026, according to Japan IR.

That result gives the long-term forecast a fresh earnings reference, but the next test is execution. Rohto operates across eye care, skin care, internal medicines, cosmetics, functional foods and medical businesses, so the overseas-sales target will require growth across several product categories rather than a single launch.

Analysts see room above JPY 2,718

The market data show a mixed short-term picture. Rohto was last at JPY 2,718 on October 6, 2026, down 0.29 percent from JPY 2,726, while the 52-week range ran from JPY 2,218.50 to JPY 3,122. The stock therefore stood 12.94 percent below its 52-week high.

According to Investing.com on October 6, 2026, 11 analysts held a Buy consensus with an average 12-month target of JPY 3,290. The high target was JPY 3,840 and the low target was JPY 2,600, putting the average target 21.04 percent above the October 6 price.

Rohto stock stays below its yearly high

Rohto Pharmaceutical stock was last at JPY 2,718 on the Tokyo Stock Exchange on October 6, 2026 at 3:30 p.m. JST, down 0.29 percent on the session. The next earnings release is scheduled for November 12, 2026.